Aleve Ads Cite Specific FDA Advisory Panel Opinions On Naproxen Safety
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer steers clear of directly implying FDA endorsement of naproxen's safety by referencing mainstream media reports on the committees' discussions about COX-2 inhibitors and NSAIDs.
You may also be interested in...
Crestor Safety Defense Misrepresents FDA Position, Agency Tells Company
An AstraZeneca “patient safety” print ad that ran in mid-November “misleadingly suggests that the agency does not believe that Crestor poses safety concerns,” the FDA ad division says in an “untitled” letter to the company. The Crestor ad asserted FDA has concluded safety concerns about rosuvastatin “have no medical or scientific basis.”
NDAC Approach To OTC Switches Highlighted At Corticosteroid Meeting
Panel review provides examples of different attitudes toward switches between OTC experts, other category-specific prescribers.
Plan B Decision Expected In Coming Weeks, Barr CEO Says
Downey says Rx sales of approximately $20 mil. have restricted availability of the emergency contraceptive at pharmacies across the country.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: